Literature DB >> 468410

Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients.

T R Jerrells, J H Dean, G Richardson, G B Cannon, R B Herberman.   

Abstract

Peripheral blood mononuclear cells of most normal adults and patients with breast or lung cancer were found to inhibit [3H] thymidine uptake by lymphoid cell lines in a growth inhibition assay. At effector:target cell ratios between 5:1 and 20:1, lung cancer patients and breast cancer patients, when compared to normal individuals, demonstrated significantly greater inhibition of [3H] thymidine uptake by a human lymphoid cell line (F-265). The effector cells were adherent and were probably monocytes. Sephadex G-10 column passage or adherence to plastic removed most growth-inhibitory activity. Adherent cells recovered from plastic flasks (88-94% monocytes) were strongly growth-inhibitory. Lung cancer patients receiving BCG immunotherapy were found to have an apparently increased activity compared to patients not treated with BCG. The possible mediation of the growth inhibition by release of prostaglandins was suggested by the reduced cytostatic effects in the presence of indomethacin. Growth-inhibitory activity was not species-restricted, since human effector cells and also effector cells from tumor-bearing mice were reactive against the human target cell and against a murine lymphoma line (RBL-5). Natural killer (NK) cells did not appear to contribute appreciably to the observed cytostasis, since the levels of their activities did not correlate, and human NK cells are non-adherent and have little reactivity against F-265 or RBL-5. The inhibition of [3H]thymidine uptake by target cells was demonstrated to be a good reflection of actual inhibition of proliferation, since incubation of adherent cells from cancer patients with F-265 resulted in similar degrees of reduction in the number of target cells and in [3H] thymidine uptake.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 468410     DOI: 10.1002/ijc.2910230606

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Cytostatic activity on tumour cells of monocytes from patients with gastrointestinal cancer.

Authors:  B Mytar; M Zembala; W Uracz; A Czupryna
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

2.  Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma.

Authors:  K Nara; H Odagiri; M Fujii; Y Yamanaka; M Yokoyama; T Morita; M Sasaki; M Kon; T Abo
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Chemiluminescence, suppression and cytotoxicity in peripheral blood mononuclear cells from solid tumor cancer patients.

Authors:  D P Braun; K P De Boer; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Immunosuppression associated with the development of chronic infections with Rickettsia tsutsugamushi: adherent suppressor cell activity and macrophage activation.

Authors:  T R Jerrells
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Serial immunological testing in patients with gastric cancer.

Authors:  M Zembala; T Popiela; D Kowalczyk; B Mytar; A Pituch-Noworolska; I Ruggiero; W Uracz; A Czupryna; H Labza
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

6.  "Activated" monocytes in gastric cancer patients. II. Suppressor and cytostatic activity in vitro.

Authors:  W Uracz; B Mytar; M Zembala; I Ruggiero; T Popiela; A Czupryna
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

7.  A phase I trial of recombinant gamma interferon in patients with cancer.

Authors:  K A Foon; S A Sherwin; P G Abrams; H C Stevenson; P Holmes; A E Maluish; R K Oldham; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients.

Authors:  E Yanagawa; A Uchida; E M Kokoschka; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  "Activated" monocytes in gastric cancer patients. I. Increased Fc receptor expression, antibody-dependent cellular cytotoxicity and NBT reduction.

Authors:  W Uracz; A Pituch-Noworolska; M Zembala; T Popiela; A Czupryna
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

10.  Human bronchoalveolar macrophage cytotoxicity for cultured human lung-tumour cells.

Authors:  S Swinburne; M Moore; P Cole
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.